Logo small

Patients with PsA are waiting for reimbursement of IL-23 inhibitors

MedExpress Team

Piotr Wójcik

Published Oct. 13, 2022 08:34

Patients with PsA are waiting for reimbursement of IL-23 inhibitors - Header image
prof. Joanna Narbutt
- Dermatologists, rheumatologists, but most of all patients suffering from psoriatic arthritis, are waiting for interleukin 23 inhibitors to be reimbursed also in our country - said Prof. dr hab. n. med. Joanna Narbutt, National Consultant for Dermatology and Venereology.


What treatments are already available for patients with psoriatic arthritis and what are their needs not yet met?

Psoriatic arthritis is a very serious disease that often accompanies psoriasis. Young people often suffer from it and, if left untreated, it leads to disability. For several years we have been lucky to use modern biological therapies. We do have a large portfolio of drugs. We have TNF-alpha and interleukin 17 inhibitors. We use them after the failure of classic drugs, such as methotrexate or non-steroidal anti-inflammatory drugs, depending on the form of PsA. However, medicine, pharmacy and technology are moving forward, and therefore there are already new molecules - interleukin 23 inhibitors, which are registered in PsA. Dermatologists, rheumatologists and, above all, patients are waiting for them to be re...

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also